A systematic review and meta-analysis of BRCA1/2 mutation for predicting the effect of platinum-based chemotherapy in triple-negative breast cancer

Jia, Xiaomeng; Wang, Kainan; Xu, Lingzhi; Li, Ning; Zhao, Zuowei; Li, Man

doi:10.1016/j.breast.2022.08.012

Cited by 6 publications

(6 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…BRCAness patients tend to benefit from platinum-based therapy in prostate cancer and breast cancer [ 32 , 33 ]. As platinum-based chemotherapy is frequently used in ESCC for treatment before or after surgery, we were wondering whether patients with high BRCAness signatures could also benefit.…”

Section: Resultsmentioning

confidence: 99%

Immune-tumor interaction dictates spatially directed evolution of esophageal squamous cell carcinoma

Zhou,

Mo,

Cui

et al. 2024

National Science Review

View full text Add to dashboard Cite

Esophageal squamous cell carcinoma (ESCC) is a poor-prognostic cancer type with extensive intra- and inter-patient heterogeneity in both genomic variations and tumor microenvironment (TME). However, the patterns and drivers of spatial genomic and microenvironmental heterogeneity of ESCC remain largely unknown. Here, we generated a spatial multi-omic atlas by whole-exome, transcriptome, and methylome sequencing of 507 tumor samples from 103 patients. We identified a novel tumor suppressor PREX2, accounting for 22% ESCCs with frequent somatic mutations or hyper-methylation, which promoted migration and invasion of ESCC cells in vitro. Analysis of the tumor microenvironment and quantification of subclonal expansion indicated that ESCCs undergo spatially directed evolution, where subclones mostly originated from the tumor center but had a biased clonal expansion to the upper direction of the esophagus. Interestingly, we found upper regions of ESCCs often underwent stronger immunoediting with increased selective fitness, suggesting more stringent immune selection. In addition, distinct TMEs were associated with variable genomic and clinical outcomes. Of which, hot TME was associated with high immune evasion and subclonal heterogeneity. We also found that immunoediting, instead of CD8+ T cell abundance, acts as an independent prognostic factor of ESCCs. Importantly, we found significant heterogeneity in previously considered potential therapeutic targets, as well as BRCAness characteristics in a subset of patients, emphasizing the importance of focusing on heterogeneity in ESCC targeted therapy. Collectively, these findings provide novel insights into the mechanisms of the spatial evolution of ESCC and inform precision therapeutic strategies.

show abstract

Section: Resultsmentioning

confidence: 99%

Immune-tumor interaction dictates spatially directed evolution of esophageal squamous cell carcinoma

Zhou,

Mo,

Cui

et al. 2024

National Science Review

View full text Add to dashboard Cite

show abstract

“…TNBC’s heterogeneity has led investigations to its genetic and molecular characteristics, which have led to the identification of potential biomarkers. For instance, TNBC patients with BRCA1 gene mutations may have a better response to platinum-based chemotherapy [ 50 ].…”

Section: Discussionmentioning

confidence: 99%

The Response of Triple-Negative Breast Cancer to Neoadjuvant Chemotherapy and the Epithelial–Mesenchymal Transition

Zapperi

Porta

2023

IJMS

View full text Add to dashboard Cite

It would be highly desirable to find prognostic and predictive markers for triple-negative breast cancer (TNBC), a strongly heterogeneous and invasive breast cancer subtype often characterized by a high recurrence rate and a poor outcome. Here, we investigated the prognostic and predictive capabilities of ARIADNE, a recently developed transcriptomic test focusing on the epithelial–mesenchymal transition. We first compared the stratification of TNBC patients obtained by ARIADNE with that based on other common pathological indicators, such as grade, stage and nodal status, and found that ARIADNE was more effective than the other methods in dividing patients into groups with different disease-free survival statistics. Next, we considered the response to neoadjuvant chemotherapy and found that the classification provided by ARIADNE led to statistically significant differences in the rates of pathological complete response within the groups.

show abstract

“…In TNBC, carboplatin has demonstrated high efficacy in patients with known tumors carrying variations in BRCA1 and BRCA2 [32]. Moreover, there is evidence that patients with variations in other HR genes, aside from BRCA1 and BRCA2, can benefit from platinum-based treatment.…”

Section: Platinum-based Chemotherapy In Hhr Mutated Prostate Cancermentioning

confidence: 99%

Platinum-based chemotherapy in metastatic prostate cancer: what possibilities?

Catalano,

Lapucci,

Nobili

et al. 2023

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

Metastatic prostate cancer is a major health burden worldwide, necessitating the continuous development of effective treatment strategies. Androgen deprivation therapy remains the cornerstone of prostate cancer treatment, but novel approaches are needed for metastatic castration-resistant prostate cancer (mCRPC). Recent studies have highlighted the prevalence of mutations in DNA repair genes, including BRCA1 and BRCA2, in mCRPC patients, rendering them more susceptible to platinum-based chemotherapy and Poly (ADP-ribose) polymerase (PARP) inhibitors. Platinum-based chemotherapy, particularly in combination with taxanes, has demonstrated encouraging activity in mCRPC, as well as homologous recombination gene alterations have shown increased sensitivity to platinum compounds in these patients. The combination of platinum-based chemotherapy with PARP inhibitors represents a novel and potentially effective therapeutic strategy for this subgroup of patients. However, the optimal sequence of administering these agents and the potential for cross-resistance and cross-toxicities remain areas requiring further investigation. Prospective randomized studies are essential to elucidate the most effective treatment approach for this challenging patient population. This review aims to explore the potential of platinum-based chemotherapy in the context of prostate cancer, and more in detail in homologous recombination repair (HRR) mutated patients. We discuss the synergistic effects of combining platinum compounds with PARP inhibitors and the potential benefits of adopting specific therapeutic sequences.

show abstract

A systematic review and meta-analysis of BRCA1/2 mutation for predicting the effect of platinum-based chemotherapy in triple-negative breast cancer

Cited by 6 publications

References 41 publications

Immune-tumor interaction dictates spatially directed evolution of esophageal squamous cell carcinoma

Immune-tumor interaction dictates spatially directed evolution of esophageal squamous cell carcinoma

The Response of Triple-Negative Breast Cancer to Neoadjuvant Chemotherapy and the Epithelial–Mesenchymal Transition

Platinum-based chemotherapy in metastatic prostate cancer: what possibilities?

Contact Info

Product

Resources

About